Enzalutamide (MDV3100) is a drug that blocks the hormone testosterone from binding to a protein on cells called the androgen receptor. It is approved for the treatment of men with advanced prostate cancer. Researchers believe that blocking the androgen receptor may also slow or stop tumor growth in patients with ovarian, fallopian tube, or primary peritoneal cancers that contain the androgen receptor.
In this study, researchers are evaluating the safety and effectiveness of enzalutamide for the treatment of women with advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancers that contain the androgen receptor. Enzalutamide is a capsule that is taken orally (by mouth).